Immunomodulators: use in combined therapy against leishmaniasis

References

• Tripathi P, Singh V, Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol. Med. Microbiol.51(2), 229–242 (2007).
   PubMedGoogle Scholar
• Goto H, Lindoso JA. Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev. Anti Infect. Ther.8(4), 419–433 (2010).
   PubMed Web of Science ®Google Scholar
• Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol.22(12), 552–557 (2006).
   PubMed Web of Science ®Google Scholar
• Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol.5(11), 873–882 (2007).
   PubMed Web of Science ®Google Scholar
• Kaye PM, Svensson M, Ato M et al. The immunopathology of experimental visceral leishmaniasis. Immunol. Rev.201, 239–253 (2004).
   PubMed Web of Science ®Google Scholar
• Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. Br. Med. J.326(7385), 377–382 (2003).
   PubMed Web of Science ®Google Scholar
• Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet366(9496), 1561–1577 (2005).
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med.362(6), 504–512 (2010).
   PubMed Web of Science ®Google Scholar
• van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis.10(3), 184–194 (2010).
   PubMed Web of Science ®Google Scholar
• Alvar J, Croft S, Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol.61, 223–274 (2006).
   PubMed Web of Science ®Google Scholar
• Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun.68(1), 288–293 (2000).
   PubMed Web of Science ®Google Scholar
• Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother.45(8), 2185–2197 (2001).
   PubMed Web of Science ®Google Scholar
• Fernandez-Guerrero ML, Aguado JM, Buzon L et al. Visceral leishmaniasis in immunocompromised hosts. Am. J. Med.83(6), 1098–1102 (1987).
   PubMed Web of Science ®Google Scholar
• Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Invest.83(4), 1253–1257 (1989).
   PubMed Web of Science ®Google Scholar
• Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular leishmania donovani infection: gamma interferon plus pentavalent antimony. J. Infect. Dis.157(5), 973–978 (1988).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J. Infect. Dis.170(3), 659–662 (1994).
   PubMed Web of Science ®Google Scholar
• Badaro R, Falcoff E, Badaro FS et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med.322(1), 16–21 (1990).
   PubMed Web of Science ®Google Scholar
• Nabors GS, Afonso LC, Farrell JP, Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl Acad. Sci. USA92(8), 3142–3146 (1995).
   PubMed Web of Science ®Google Scholar
• Murray HW, Montelibano C, Peterson R, Sypek JP. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis.182(5), 1497–1502 (2000).
   PubMed Web of Science ®Google Scholar
• Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines6(5), 835–847 (2007).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol.3(2), 196–200 (2002).
   PubMed Web of Science ®Google Scholar
• Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis.3(7), e491 (2009).
   PubMed Web of Science ®Google Scholar
• Badaro R, Nascimento C, Carvalho JS et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J. Infect. Dis.170(2), 413–418 (1994).
   PubMed Web of Science ®Google Scholar
• Zubairi S, Sanos SL, Hill S, Kaye PM. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol.34(5), 1433–1440 (2004).
   Google Scholar
• Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun.71(11), 6453–6462 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy ML, Cotterell SE, Gorak PM, Engwerda CR, Kaye PM. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol.161(8), 4153–4160 (1998).
   Google Scholar
• Schonfeld D, Matschiner G, Chatwell L et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc. Natl Acad. Sci. USA106(20), 8198–8203 (2009).
   PubMed Web of Science ®Google Scholar
• Tugues S, Fernandez-Varo G, Munoz-Luque J et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology46(6), 1919–1926 (2007).
   PubMed Web of Science ®Google Scholar
• Buysschaert I, Carmeliet P, Dewerchin M. Clinical and fundamental aspects of angiogenesis and anti-angiogenesis. Acta Clin. Belg.62(3), 162–169 (2007).
   PubMed Web of Science ®Google Scholar
• Dalton JE, Maroof A, Owens BM et al. Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J. Clin. Invest.120(4), 1204–1216 (2010).
   PubMedGoogle Scholar
• Wilson ME, Young BM, Davidson BL, Mente KA, McGowan SE. The importance of TGF-beta in murine visceral leishmaniasis. J. Immunol.161(11), 6148–6155 (1998).
   PubMedGoogle Scholar
• Murray HW, Lu CM, Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun.70(11), 6284–6293 (2002).
   PubMed Web of Science ®Google Scholar
• Murray HW. Interleukin 10 receptor blockade – pentavalent antimony treatment in experimental visceral leishmaniasis. Acta Trop.93(3), 295–301 (2005).
   PubMed Web of Science ®Google Scholar
• Murray HW, Flanders KC, Donaldson DD et al. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun.73(7), 3903–3911 (2005).
   PubMedGoogle Scholar